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1. Introduction 
Despite the prominent use of ferrets in medical research, the immune system of ferrets 
remains poorly characterized (Svitek & von, V, 2007). Here we describe ferret TNF-ǂ and 
IFN-Ǆ immunoassays.  
Specifically, this covers the following topics:  
 Background: The use of ferrets in medical research 
 TNF-ǂ and IFN-Ǆ cloning and sequencing 
 Expression and purification of recombinant ferret TNF-ǂ and IFN-Ǆ proteins 
 Cytokine real-time PCR based assays  
 Development of IFN-Ǆ and TNF-ǂ hybridoma clones  
 ELISA and ELISPOT assays for the ferret cytokine IFN-Ǆ  
2. Background 
This Background describes the current use of ferrets in medical research but also includes a 
description of past uses. The importance of ferrets is highlighted in human disease modeling 
and in prophylactic and vaccine development. The various uses of ferrets in medical 
research demonstrate the need for immune profiling reagents and assays.  
2.1 Biology of the ferret 
The ferret, Mustela putorius furo, is a relatively small and inexpensive animal in terms of its 
potential for research use, although mice remain the traditional influenza model for virus 
pathogenesis.  
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Essentially, mice are low cost animals that have a broad availability of corresponding 
reagents for immunological investigation. Mice are easily mutated and there exists a 
plethora of currently available transgenic mice with immune targeted gene deletions or gene 
knock-ins (Belser, Szretter, Katz, & Tumpey, 2009). Two factors against the use of mice in 
influenza immune studies are 1) most human influenza strains must be mouse adapted 
prior to initiation of infection studies due to the inability of human influenza viruses to 
replicate in the mouse and 2) mice do not exhibit human-like clinical signs of influenza such 
as sneezing and temperature fluxes. 
In contrast to mice, ferrets do develop respiratory illnesses that are similar to human 
disease. Although the ferret is not considered a large laboratory animal, it is able to provide 
many biological samples for pathological testing during an infection study. For instance, 
frequent and sizable blood sampling is feasible in the ferret that is not practical in smaller 
rodents such as in mice and rats.  
Furthermore, clinical features of disease are easily observed. Such as clinical fever 
manifested as an elevation in body temperatures can be detected as early as 1 day following 
infection with many viruses. Our own as well as previously published studies have shown 
that high fevers can persist for many days following infection of viruses such as H1N1pdm 
influenza (Rowe et al., 2010b; Sweet et al., 1979; Zitzow et al., 2002). As well as fever, nasal 
discharge, sneezing and activity level can also be observed in ferrets infected with influenza 
viruses (Rowe et al., 2010b). Taken together, these clinical features along with the feasibility 
for blood and pathological sampling suggest the ferret to be an optimal animal for the study 
of human infectious diseases, including influenza viruses. For example, our group has 
recently used the ferret model successfully to characterize and compare immunopathology 
caused by several strains of currently circulating influenza A and B viruses (Huang et al., 
2011).  
2.2 Respiratory viral infections 
Viral respiratory infectious diseases are a major worldwide concern which causes significant 
morbidity and mortality (Kolling et al., 2001). Respiratory viral diseases such as the severe 
acute respiratory syndrome coronavirus (SARS-CoV), avian influenza H5N1 and pandemic 
influenza H1N1 virus are potential epidemic and/or pandemic threats (Dushoff, Plotkin, 
Viboud, Earn, & Simonsen, 2006; Weiss & McMichael, 2004; Dawood, Dalton, Durrheim, & 
Hope, 2009; Dawood et al., 2009). Specifically, influenza is a significant contributor to 
morbidity and mortality worldwide and is the focus of our laboratory and the focus disease 
of this chapter.  
The World Health Organization estimates the burden of season influenza to be 
approximately one billion cases annually, including 3-5 million severe cases and 300,000-
500,000 deaths (Girard, Cherian, Pervikov, & Kieny, 2005). Influenza illness in humans is 
caused by an influenza RNA virus of the Orthomyxoviridae family. The influenza virus can 
be categorized as one of three types: A, B, or C (Steinhauer & Skehel, 2002). Importantly, the 
influenza viral genome is susceptible to two primary types of genetic mutations that cause 
variation in the immunogenic proteins and subsequently in disease presentation and clinical 
features (Kasowski, Garten, & Bridges, 2011; Steinhauer & Skehel, 2002). Firstly, antigenic 
drift is defined by minor changes to the viral genome introduced during virus RNA 
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replication (Steinhauer & Skehel, 2002). Second, antigenic shift is when a host is infected by 
various influenza strains at the same time allowing entire genome segments to be reassorted 
during co-infection. This results in novel influenza strains markedly distinct from their 
progenitors (Steinhauer & Skehel, 2002; Kasowski et al., 2011). From these reassortments, 
novel influenza strains may arise with new clinical symptoms and disease features that have 
the potential to be highly pathogenic, easily transmissibility with pandemic potential.  
The most significant recent reassortant to emerge was the 2009 pandemic H1N1 influenza A 
(H1N1pdm) strain (Perez-Padilla et al., 2009). H1N1pdm is closely related to the reassortant 
swine influenza A viruses previously isolated in North America, Europe, and Asia 
(Trifonov, Khiabanian, & Rabadan, 2009). Infection with H1N1pdm resulted in diverse 
clinical outcomes. The majority of reported cases were mild and self-limiting (Gilsdorf, 
Poggensee, & Working Group, 2009; Nicoll & Coulombier, 2009; Writing Committee of the 
WHO Consultation on Clinical Aspects of Pandemic, 2010) and typical symptoms include 
fever, sore throat, malaise, and headache (Health Protection Agency, Health, National Public 
Health Service for Wales, & HPA Northern Ireland Swine influenza investigation team, 
2009). A small proportion of pandemic influenza cases required hospitalization and patient 
ventilator support (Centers for Disease Control and Prevention (CDC), 2009; Kumar et al., 
2009; Perez-Padilla et al., 2009; Writing Committee of the WHO Consultation on Clinical 
Aspects of Pandemic, 2010). Common complications in there severe cases were severe 
hypoxemia, shock, pneumonia, and acute respiratory distress syndrome (ARDS)(Perez-
Padilla et al., 2009; Kumar et al., 2009; Centers for Disease Control and Prevention (CDC), 
2009). Nonpulmonary acute organ dysfunction has also been reported (Uyeki, Sharma, & 
Branda, 2009; Kumar et al., 2009). Since ferrets show signs of illness and are easily infected 
with human strains of H1N1pdm, we are currently investigating and have published on the 
immunopathogenic mechanisms and possible therapeutics for H1N1pdm illness in ferrets 
(Rowe et al., 2010a; Huang S.S.H. et al., 2011; Cameron et al., 2008).  
2.3 Host immune responses 
Host immunity can be broken down into an innate and adaptive immune response. The 
innate immune response is a nonspecific attack on the invading agent while the adaptive 
immune response is an attack tailored to the individual pathogen (Ryan & Majno, 1977). 
What determines the type of triggered immune response is the invading agent itself. The 
agent is recognized first by the innate immune arm and together the innate and adaptive 
immune responses lead to a unique immune signature that for each pathogen. Furthermore, 
the clinical outcome is the biological consequence of the immune response that has 
developed toward the pathogen (Belz, Bedoui, Kupresanin, Carbone, & Heath, 2007; Zheng 
et al., 2007).  
In order to evaluate the immune response during the course of viral infection, it is important 
to be able to determine the activity of the immune cells. Cell identity and their activation 
status are distinguished by the molecules expressed at the cell surface. Furthermore, cells of 
the immune system can be described as innate or adaptive immune cells. Innate immune 
cells include neutrophils, esosinophils, basophils, macrophages and NK cells. Adaptive 
immune cells include T lymphocytes, B lymphocytes and Dendritic cells (Hauge, Madhun, 
Cox, Brokstad, & Haaheim, 2007). Many of these cells have yet to be characterized in the 
ferret.  
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As well as understanding the cell activation and cellular populations during an immune 
response, it is also important to elucidate the intracellular activation and intercellular events 
which occur following infection. Cells are often activated by cytokines, soluble extracellular 
proteins that mediate signals from one cell to another. Once the cell has been in contact with 
a cytokine, intracellular signalling cascades are activated. The activation of these signalling 
cascades leads to cell effector function.  
One of the most prominent branches of cytokine-cell signalling events is of the 
inflammatory interferon (IFN) cytokines which connect the innate immune response with 
the activation of the adaptive immunity. The IFN family of cytokines can be categorized as 
either Type I IFN or Type II. IFN-ǂ and IFN-ǃ are of the Type I IFN cytokines and have a 
prominent role during viral infection. IFN-Ǆ is of the Type II IFN family. IFN-Ǆ also plays a 
role in viral infections but also functions during bacterial infections.  
The release of IFN-Ǆ leads to cellular activation through signalling pathways. Ligation of the 
interferon receptors 1 and 2 (IFNAR1 and IFNAR2 for IFN-ǂ and IFN-ǃ; IFNGR1 and 
IFNGR2 for IFN-Ǆ) with an IFN cytokine induces IFN signaling pathways and promotes IFN 
gene induction. Both the Type I and Type II cytokines signal through JAK-STAT pathways 
to activate IFN genes and promote immune responses (Marijanovic, Ragimbeau, van der 
Heyden, Uze, & Pellegrini, 2007). IFN induced JAK-STAT signalling often involves 
interferon regulatory factor 9 (IRF9) (Takaoka & Yanai, 2006). The interferon stimulatory 
factor 3 complex (ISGF3) binds to interferon-stimulated response element (ISRE) and 
activates transcription of IFN-ǂ inducible genes, including 2'–5' oligoadenylate synthase 1 
(OAS1), myxovirus resistance 1 (MX1), interferon stimulated gene 15 (ISG15) and many 
other IFN-response genes (IRGs) (Uddin & Platanias, 2004). The expression of IFN-Ǆ-
induced protein IP10, or CXCL10, following IFN stimulation, is often considered a hallmark 
of virus infection in host organisms. IFN-ǂ stimulation ultimately promotes a cellular 
antiviral state which is hallmarked by the upregulation of IRGs (Chevaliez & Pawlotsky, 
2009). Although IFN signalling gene upregulation during viral infection has been the subject 
of previous reports, there is little information regarding the host immune responses directly 
induced by viruses versus those that are upregulated due to secondary IFN stimulation 
(Chelbi-Alix & Wietzerbin, 2007; Haagmans et al., 2004; Loutfy et al., 2003; Cameron et al., 
2007). Therefore there is a need for the study of IFN signalling and IFN stimulated events 
during viral infection which can be investigated using the ferret model.  
TNF (Tumor Necrosis Factor) -ǂ is a cytokine produced mainly by activated macrophages 
and T-lymphocytes, and exerts a multitude of biological activities including cytotoxic effects 
upon certain tumours and virus- infected cells, immunomodulation, and regulation of 
cellular proliferation (Vilcek & Lee, 1991). TNF-ǂ is a potent inhibitor of influenza 
replication in vitro (Seo & Webster, 2002), and the induction of TNF-ǂ expression has been 
associated with ARDS-like symptoms in H5N1 infected mice (Xu et al., 2006). Depletion of 
TNF-ǂ in influenza or respiratory syncytial virus-infected animals significantly reduced 
pulmonary inflammation and cytokine production without compromising viral clearance, 
and almost completely abolished any associated weight loss and observable illness (Hussell, 
Pennycook, & Openshaw, 2001). There is evidence to suggest that hyper-production of TNF-
ǂ contributes to the high degree of virulence exhibited by H5N1 strains in humans. Using 
primary cultures of human monocyte-derived macrophages, Cheung et al. demonstrated a 
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significant increase in TNF-ǂ gene transcription and protein expression in H5N1-infected 
cells compared to that of H1N1- or H3N2- infected cells (Cheung et al., 2002). Dysregulation 
of cytokines, including TNF-ǂ, is thought to contribute to the immunopathogenesis of 
influenza and SARS CoV virus infections, however, the in vivo mechanism is unknown.  
2.4 Examining the ferret host immune response in respiratory diseases 
When infected with respiratory viruses ferrets display many of the symptoms and 
pathological features seen in infected humans (Darnell et al., 2007; Martina et al., 2003; 
Peltola, Boyd, McAuley, Rehg, & McCullers, 2006). The ferret model has been used in 
influenza research since the influenza virus was first isolated (Bouvier & Lowen, 2010; 
Lambkin et al., 2004; Small, Jr., Waldman, Bruno, & Gifford, 1976). Importantly, ferrets and 
humans have similar lung physiology allowing influenza to infect both species through a 
comparable mechanism, sialic receptors the host receptor for influenza (Maher & DeStefano, 
2004; van et al., 2007). Furthermore, as ferrets are highly susceptible to influenza virus, they 
can also transmit the influenza virus from infected to healthy ferrets (Smith et al., 1933).  
As well as influenza, ferrets have shown promise as a model for other respiratory viruses 
such as Severe Acute Respiratory Syndrome Corona virus (SARS Covirus), the BSL-4 Nipah 
virus and morbilliviruses and other pathogens such as gastro-intestinal bacteria and prions 
(Bouvier, Lowen, & Palese, 2008; van den Brand et al., 2008; Bossart et al., 2009; Svitek & 
von, V, 2007; ter et al., 2006; Martina et al., 2003).  
2.5 The use of ferrets for the investigation of influenza therapeutics 
Not only are ferrets useful for infectious disease modeling but they are also a good platform 
for testing and developing viral therapeutics. Currently ferrets are used for influenza drug 
testing; for example, neuraminidase inhibitors are effective during ferret influenza infection 
(Mendel et al., 1998; Govorkova et al., 2007; Yun et al., 2008). As well, ferrets display 
immunological memory and are thus useful for testing the safety and efficacy of vaccines 
(Bouvier & Lowen, 2010; Maher & DeStefano, 2004; Gupta, Earl, & Deem, 2006). Ferrets have 
been used to investigate SARS and influenza vaccines (Bouvier & Lowen, 2010; Maher & 
DeStefano, 2004; Gupta et al., 2006). 
Previously, we sought to elucidate the ferret immune response during viral infection and 
identify potential therapeutic drug targets (Danesh et al., 2011). We investigated the genetic 
programs and cell signaling pathways that were regulated by SARSCoV infection compared 
to IFN-ǂ2b stimulation in the ferret model (Danesh et al., 2011). The phosphorylation status 
of signaling molecules in IFN-ǂ2b-stimulated peripheral blood mononuclear cells (PBMCs) 
was examined with the end of identifying kinase inhibitors that may be useful in SARS 
pathogenesis. We found IFN-ǂ2b caused STAT1 phosphorylation in in vitro experiments 
(Danesh et al., 2011). Importantly, gene expression profiles of PBMCs as well as lung 
necropsies of SARS-CoV-infected ferrets identified 7 upregulated IRGs that were similarly 
upregulated in response to IFN-ǂ2b injection (Danesh et al., 2011). In summary, IFN-ǂ2b 
injection and SARS-CoV infection led to both similar as well as unique gene expression 
signatures (Danesh et al., 2011). Taken together, increased knowledge of these gene 
expression signatures and signalling pathways will improve the understanding of the ferret 
immune system and lead to possible therapeutic drug targets. 
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2.6 Recent advances in ferret reagent development 
Although researchers are able to use direct infection of human influenza strains and monitor 
biological clinical signs with the ferret model, there is a paucity of reagents for influenza 
investigative studies in the ferret. As well, there is a lack of information on the ferret 
immune system that has slowed the progress of this system. Specifically, the lack of ferret 
specific antibodies capable of detecting surface molecules of immune cells and reagents for 
ferret inflammatory mediators such as cytokines has hindered the immune profiling in ferret 
infectious disease models.  
Recently, we reported the characterization of the ferret chemokines, CXCL9, CXCL10 and 
CXCL11, which are important in migration of mononuclear cells to sites of infection (Danesh 
et al., 2008). We have previously characterized ferret cytokine and chemokine genes as well 
as have developed immunological assays for evaluating the ferret immune system following 
SARS and influenza infection (Cameron et al., 2008; Danesh et al., 2008; Ochi et al., 2008). As 
both IFN-Ǆ and TNF-ǂ are significant hallmarks of adaptive immunity, these cytokines are 
useful markers when studying the viral immune response.  
3. Ferret immunoassays 
3.1 TNF-α and IFN-γ cloning and sequencing 
The methods used for cloning ferret TNF-ǂ and IFN-Ǆ genes are covered in this section. 
ClustalW alignments of ferret genes with orthologues from other mammalian species such 
as canine are also shown.  
3.1.1 Methods 
Animals  
Six-month-old male ferrets (Mustela putorius furo) were obtained from Triple F Farms Inc. 
(Sayre, Pa. USA). Animals were housed at Toronto General Research Institute animal facility 
and the animal use protocol was approved by the animal care committee of the University 
Health Network, Toronto, Ontario. Animals were quarantined and monitored for one week 
before tissue, blood collection and project initiation. Animal diets are based on a low fat, 
high protein regimen, recommended by Triple F Farms for small carnivores.  
Total RNA purification of ferret IFN-γ and TNF-α 
Ferret whole blood was diluted at a ratio of 1:1 with RPMI (Invitrogen, Mississauga, Canada) 
and blood was stimulated with mitogens, LPS (1ug/ml, Sigma Chemicals, St. Louise, MO, 
USA), PMA (50 ng/ml, Sigma), ionomycin (0.1 mM, Sigma) or poly I:C (25 μg/ml, Sigma) by 
incubating at 37ºC in 5% CO2 for 2, 4, 8, and 12 hrs. Following cell stimulation, RNA was 
isolated using the Paxgene RNA isolation method (Qiagen, Missisauga, Canada) according to 
manufacturer’s protocols. cDNA was synthesized from purified total RNA by reverse 
transcriptase II (Invitrogen) according to supplier’s instructions. 
Cloning, sequencing and expression of ferret TNF-α and IFN-γ 
Gene specific primers were used to amplify ferret TNF-ǂ and IFN-Ǆ by PCR. Primers were 
designed based on highly conserved regions of the nucleotide gene sequences. These 
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regions were identified through ClustalW-based multiple sequence alignments of the TNF-ǂ 
and IFN-Ǆ genes from several species (ClustalW 1.83, European Bioinformatics Institute 
(http://www.ebi.ac.uk/clustalw/) and are shown in Table 1. Accession numbers used for 
ClustalW alignments of INF-Ǆ are as follows: Eurasian badger; Y11647, rabbit; P30123, cat; 
P46402, dog; P42161, mouse; P01580, and human; P01579. The Gene peptide accession 
numbers for IFN-Ǆ are: badger, CAA72346; dog, AAD314233; panda, ABE02189; cat, 
BAA06309; rhinoceros, ABC18310; donkey, AAC42595; pig, ABG56234; dolphin, BAA82042; 
sheep, ABD64367; buffalo, BAE75855; cow, NP_776511; armadillo, AAZ57195; woodchuck, 
AAC31963; rabbit, BAA24439; human, P01579; monkey, AAM21477; mouse, P01580; rat, 
NP_620235; chicken, CAA69227; zebrafish, BAD06253. 
 
Table 1. Primers used to clone and express full length cDNA for ferret TNF-ǂ  
To ensure correct sequencing of 3’ and 5’ cDNA ends or the genes, we used RNA ligase-
mediated rapid amplification of cDNA ends (RLM-RACE) as per manufacturer’s 
instructions (FirstChoice RLM-RACE Kit, Ambion, Ausin, Texas, USA). Briefly, 1-2μg of 
total RNA from mitogen-stimulated ferret blood cells (described above) was used as starting 
material. The RNA was treated with calf intestinal alkaline phosphatase (CIP) and 
subsequently with tobacco acid pyrophosphate (TAP). RNA adapter was ligated and the 
RNA was reverse transcribed to cDNA followed by PCR amplification with nested primers 
(outer and inner) to adapter and gene (for TNF-ǂ see Table 1.). 3’ RACE was also performed 
as per manufacturer’s protocol with gene-specific nested primers (Table 1.).  
The primers were tested in silico using Primer Express (Applied Biosystems). Standard PCR 
was performed using these consensus primers and template cDNA. Bands at the 
appropriate size were excised, gel purified and sub-cloned into pCR2.1-TOPO vector 
(Invitrogen). DNA sequences of positive clones were confirmed by sequencing with ABI 
3730XL DNA analyzers (Center for Applied Genomics, Toronto, ON, Canada). Gene 
identification was confirmed using Basic Local Alignment Search Tool (BLAST) analyses 
against the National Centre for Biotechnology Information databases. 
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3.1.2 Results 
Cloning and sequencing of the ferret TNF-α and IFN-γ genes  
To determine the consensus regions for both ferret TNF-ǂ and IFN-Ǆ ClustalW analysis was 
performed for human, cat and dog TNF-ǂ and IFN-Ǆ nucleotide sequences. The coding 
region for all three species was predicted to encode a 702 bp transcript and a 501 bp 
transcript, respectively for TNF-ǂ and IFN-Ǆ.  
Using the consensus sequence for TNF-ǂ and IFN-Ǆ genes, forward and reverse primers 
(Table 1. for TNF-ǂ) were designed and used to amplify full-length ferret TNF-ǂ and IFN-Ǆ 
from a ferret cDNA library derived from mitogen-stimulated ferret PBMCs. When 
necessary, RACE was used to identify the endogenous ferret sequences at the 5’ and 3’ ends 
of the transcript. The nucleotide sequence of ferret TNF-ǂ and IFN-Ǆ (previously published 
(Ochi et al., 2008)) are shown in Figure 1. and Figure 2., respectively. In addition to the 702 
bp coding region, we have determined the sequence of the 65 bp 5’ and 175 bp 3’ 
untranslated regions, respectively.  
 
The ferret cDNA was 942 bp, and the predicted protein 314 aa. Numbers on the right indicate cDNA bp. 
The 5’-UTR was 65 base pairs, the complete coding region of 702 base pairs, and 175 bp of the 3’UTR. 
Calculated molecular weight (MW) of the predicted protein is indicated at the bottom. 
Fig. 1. Full-length ferret TNF-ǂ cDNA nucleotide sequence and predicted amino acid 
sequence.  
Multiple amino acid sequence alignment revealed that the predicted ferret TNF-ǂ protein 
shares a high level of homology with cat (91% similarity) and dog (95% similarity) 
sequences (Figure 3). The sequence similarity to ferret TNF-ǂ was lower when compared to 
human (78%) and mouse (88%) TNF-ǂ sequences. The TNF ligand family consists of 19 
proteins characterized by a conserved C-terminal domain called the TNF-ǂ homology 
domain (THD) (Bodmer et al., 2002). The ferret TNF-ǂ THD domain was found to be 
significantly conserved with dog and cat TNF-ǂ sequences (Figure 3).  
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Full length ferret IFN-Ǆ cDNA sequence including 80 base pairs in the 5’ untranslated region (UTR), 501 
base pairs of coding sequence with predicted amino acid sequence, and 404 base pairs in the 3’UTR. 
Fig. 2. Ferret IFN-Ǆ cDNA (Ochi et al., 2008).  
 
Conserved regions of the TNF-ǂ homology domains (THD) are indicated by the highlighted regions. The 
table below indicates the overall aa homology (including conservative substitution) with ferret TNF-ǂ. 
Fig. 3. Multiple protein sequence alignment analysis of TNF-ǂ from various species.  
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A clustal alignment of the amino acid sequences of ferret, Eurasian badger, rabbit, cat, dog, 
mouse, and human IFN-Ǆ was performed using the ClustalW program. In contrast to ferret 
TNF-ǂ, INF-Ǆ amino acid clustal alignment showed the predicted ferret IFN-Ǆ most similar 
to the Eurasian badger (Meles meles) (97%), followed by the canine (86%) and feline (83%) 
sequences (Figure 4) (Ochi et al., 2008). The homology of ferret IFN-Ǆ to human and mouse 
IFN-Ǆ was 63% and 48%, respectively. Phylogenetic tree, previously published by our group 
(Ochi et al., 2008) depicting the relationship of IFN-Ǆ to its orthologues, shows the proximity 
of ferret IFN-Ǆ to badger (Figure 5) .  
 
Alignment of the amino acid sequences of ferret, Eurasian badger, rabbit, cat, dog, mouse, and human 
IFN-Ǆ precursor proteins is shown. Asterisks indicate positions of identical amino acid residues in all 
sequences.  Periods indicate positions with semiconserved substitutions. Amino acid homology score 
between ferret IFN-Ǆ and orthologues are shown in the lower panel. 
Fig. 4. Ferret IFN-Ǆ amino acid clustal alignment (Ochi et al., 2008).  
3.2 Development of recombinant TNF-α and IFN-γ proteins 
The cloning of ferret TNF-ǂ and IFN-Ǆ are detailed in the following section, including the 
primers used, PCR program, and vector generation. We present expression of the sub-
cloned genes in COS-7 cells by SDS-PAGE and flow cytometry. 
3.2.1 Methods 
Generation of an expression vector for ferret TNF-α and IFN-γ inflammatory cytokines  
PCR was used to engineer a Kozak sequence at the 5’ end of the ferret TNF-ǂ and IFN-Ǆ 
open reading frames, and the 3’ termination codons were removed by PCR prior to 
subcloning into the pcDNA3.1/ His6.V5/ TOPO expression vector (Invitrogen). Removal of 
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the termination codon enabled the cloned gene to be expressed as a fusion protein with two 
C-terminal epitope tags, His6 and V5.  
 
Phylogenetic tree analysis showing the relationship between ferret and other known vertebrate IFN-Ǆ 
sequences. This tree was constructed using ClustalW and MEGA 3.1 packages and bootstrapped 10,000 
times. †Bootstrapping confidence values are between 66 and 100.  
Fig. 5. Ferret IFN-Ǆ phologenetic analysis (Ochi et al., 2008).  
Transfection and purification of recombinant His-tagged TNF-α  
COS-7 cells (ATCC, Manassas, Virginia, USA) were maintained in Dulbecco’s modified 
eagle’s medium (DMEM), supplemented with 10% fetal bovine serum (Invitrogen) at 37ºC, 
5% CO2. COS-7 cells (1x107) were transfected with Effectene transfection reagent according 
to manufacturer’s instructions (Qiagen, Mississauga, Ontario, Canada). Twenty-four to 
forty-eight hours following transfection, the cell culture media from the cells were run 
through Ni-NTA metal immobilized affinity columns to bind the His-tagged recombinant 
protein (Novogen, Oakville, ON, Canada). The columns were washed and the protein was 
eluted according to the manufacturer’s protocols. Fractions containing the recombinant 
proteins were pooled and dialyzed against phosphate buffered saline (PBS) at 4ºC and 
subsequently concentrated by spin column (Nanosep 10k OMEGA, Pall Life Science,East 
Hills, NY, USA). TNF-ǂ and IFN-Ǆ protein concentrations were determined by protein assay 
kit (Pierce, Rockford, IL, USA). 
Expression and purification of GST-IFN-γ using a bacterial expression system 
Ferret IFN-Ǆ cDNA was subcloned into pGEX-6P1 vector (GE Healthcare) and purified as a 
GST fusion protein from Escherichia coli strain BL21 (DE3) by glutathione affinity 
chromatography.  
Western Blot analysis  
SDS-Poylacrylamide gel electrophoresis (10-15% SDS-PAGE) was performed with pre-cast 
gels (Bio-Rad, Hercules, CA, USA) according to standard protocols. Protein blots were 
blocked with 5% milk protein in 0.01% Tween-20 in PBS (T-PBS) for 1 hour at room 
www.intechopen.com
 
Trends in Immunolabelled and Related Techniques 144 
 
The expression construct encoding full-length ferret TNF-ǂ was transfected into COS-7 cells and 
purified using with ion (Ni2+) immobilized affinity chromatography. The eluted protein fractions were 
subjected to SDS-PAGE and western blotting. Arrow depicts the band at predicted molecular weight of 
ferret TNF-ǂ. W3 denotes wash fraction 2, and E1 and E2 denote elution fractions 1 and 2.  
Fig. 6. Purified recombinant ferret TNF-ǂ protein molecular weight determined by western 
blot analysis.  
 
Detection of recombinant ferret IFN-Ǆ by polyclonal antibody-specific immunoblotting. 
Fig. 7. Detection of ferret recombinant IFN-Ǆ.  
temperature followed by an incubation of 16 hours at 4°C with mouse-anti-His6 primary 
antibody (Invitrogen) at 508 ng/ml concentration or monoclonal anti-V5 Ab (1:1000) 
(Invitrogen). The blots were washed and incubated with goat-anti-mouse-HRP secondary 
antibody (Santa Cruz, Santa Cruz, CA, USA). Bands were visualized using enhanced 
chemiluminiscent (ECL) reagents according to manufacturer’s protocol (GE Healthcare, 
Peterborough, Ontario, Canada). 
3.2.2 Results 
Expression and purification of the recombinant ferret TNF-α and IFN-γ  
In order to obtain recombinant ferret TNF-ǂ and IFN-Ǆ protein to be used in immunoassays 
and monoclonal antibody generation, TNF-ǂ and IFN-Ǆ genes were first subcloned. 
Specifically, TNF-ǂ and IFN-Ǆ cDNA were individually subcloned into expression plasmid to 
generate expression tag fusion proteins (described previously). Ferret TNF-ǂ was expressed 
and purified from a mammalian cell line and IFN-Ǆ from a bacterial expression system. 
The native human TNF-ǂ polypeptide is cleaved at amino acid 76 to form the mature TNF-ǂ 
signal peptide at 17215 Da (Wang et al., 1985). We predicted the ferret signal sequence 
cleavage site to be at the junction of 46 and 47 by SignalP 3.0 analysis. The observed 
molecular weight of ferret TNF-ǂ according to our results was closer to that of human TNF-
ǂ at 25.7 kDa (including the His6 and V5 tags). In agreement, western blot analysis of the 
eluted fractions of ferret TNF- ǂ protein purified from COS-7 transfected cell media resulted 
in a single band of approximately 25.7 kDa molecular weight (Figure 6). 
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For IFN-Ǆ, purified recombinant ferret IFN-Ǆ protein was expressed as a GST fusion protein 
and purified from chemically competent E. coli cells. Ferret recombinant IFN-Ǆ protein 
migrated as a 40 kDa band when subjected to SDS-PAGE and western blotting using a 
polyclonal anti-IFN-Ǆ antibody (Figure 7). 
3.3 Cytokine real-time PCR based assay  
Cytokines are important inflammatory and immune mediators. Here we present primers 
designed using ClustalW alignment analysis for studying ferret cytokines by real-time PCR.  
3.3.1 Methods 
ClustalW analysis for cytokine primer design 
Cytokine Primers were designed as previously described (Section: Cloning, sequencing and 
expression of ferret TNF-ǂ and IFN-Ǆ in 4.2.1). Gene specific primers were designed based 
on highly conserved regions of orthologue nucleotide gene sequences. Conserved regions 
were identified through ClustalW-based multiple sequence alignments of the orthologues 
from several species using the ClustalW 1.83 from the European Bioinformatics Institute 
(http://www.ebi.ac.uk/clustalw/). The Primers are presented in Tables 2, Table 3 and 
Table 4. 
 
Table 2. Ferret Interleukine Primers 
IL-1alpha F ACCCACTTCATGAGGACTGC 
IL-1alpha R TGCTACTGATCTGGGCTTCA 
IL-1beta F GGACTGCAAATTCCAGGACATAA 
IL-1beta R TTGGTTCACACTAGTTCCGTTGA 
IL2 F3 CTTCGCAAACAGTGCACCTA 
IL2 R3 GCCTTCTTGGGCATGTAGAA 
IL-4 F TCACCGGCACTTTCATCCA 
IL-4 R TTCTCGCTGTGAGGATGTTCA 
IL 5 F GGGGAGGCTGTGGATAAACT 
IL 5 R CAACTTTCCGGTGTCCACTC 
IL-6 F AGTGGCTGAAACACGTAACAATTC 
IL-6 R ATGGCCCTCAGGCTGAACT 
IL-8 F AAGCAGGAAAACTGCCAAGAGA 
IL-8 R GCCAGAAGAAACCTGACCAAAG 
IL10 F CCTGTCGGAGATGATCCAGT 
IL10 R CAAGCTCACTCATGGCTTTG 
IL 11 F CTGAGCCTGTGGCCAGATA 
IL 11 R GGGAATCCAGGTTGTGGTC 
IL12B F CACCAGCAGCTTCTTCATCA 
IL12B R AGGTCTTGTCCACGCAGAGT 
IL 13 F TGGTTGACTGTGGTCATTGC 
IL 13 R GATGCCTGATTCTGGGTGAT 
IL-16 F new GGGGAGCGGATCTAGAAAAC 
IL-16 R new CGAGGAGGAGTTCAGGTCAG 
IL17A F CCTCAGCATGTGAAGGTCAA 
IL17A R AACCAGGATCTCTTGCTGGA 
IL 18 F GAGGATATGCCCGATTCTGA 
IL 18 R ATCATGGCCTGGAACACTTC 
www.intechopen.com
 
Trends in Immunolabelled and Related Techniques 146 
 
Table 3. Ferret Inflammatory Cytokine Primers 
Real-time PCR  
Real-time PCR analysis was performed as previously described (Bosinger et al., 2004). 
Briefly, experiments were carried out using the SYBR Green qPCR kit (Applied Biosystems, 
Foster City, California, USA) on an an ABI 7900 System (Applied Biosystems). The PCR 
mixture contained 25 pmol primers and 250 nmol of cDNA. Amplification was performed 
with the following program: pre-heating for 15 minutes at 95oC followed by 40 cycles of 
95oC for 15 seconds, 60oC for 1 minute, and 72oC for 1 minute. Subsequent to the completion 
of PCR amplification, the temperature was raised from annealing temperature to 95oC for 
melting curve analysis. 
 
Table 4. Ferret CC and CXC Chemokine Primers 
TNF-alpha F CCAGATGGCCTCCAACTAATCA 
TNF-alpha R GGCTTGTCACTTGGAGTTCGA 
IFN-gamma F TCAAAGTGATGAATGATCTCTCACC 
IFN-gamma R GCCGGGAAACACACTGTGAC 
CCL2 (MCP-1) F GCTCCCTATTCACTTGCTGTTTC 
CCL2 (MCP-1) R GATTCGATAGCCCTCCAGCTT 
CCL 4 F TGTGACCGTCCTTTCTCTCC 
CCL 4 R GAATCTTCCGCAGGGTGTAA 
CCL5 F GCTGCTTTGCCTACATTTCC 
CCL5 R CCCATTTCTTCTGTGGGTTG 
CCL 7 F TATCTCAACCACCTGCTGCT 
CCL 7 R GCTTGGGTTTTCTTGTCCAG 
CCL8 F CATCCCAATTACCTGCTGCT 
CCL8 R ACTGGCTGTTGGTGATCCTC 
CCL 11 F AGGTCTCCGCAGCACTTCT 
CCL 11 R TATCCTTGGCCAGTTTGGTC 
CCL 17 F CGGGAGTGCTGCCTAGAGTA 
CCL 17 R CTTCACCCTCTTGTCCTTGG 
CCL21 F TCAGGCAGAGCTATGTGCAG 
CCL21 R TCAGTCCTCTTGCAGCCTTT 
CCL22 F ACTGCACTCCTGGTTGTCCT 
CCL22 R ATCTTCACCCAGGGCACTCT 
CCL 23 F ACGAATTCGATGTGCAAACA 
CCL 23 R AGCTGGCCCCTACTACCATT 
CXCL5 F GAGCTGCGTTGTGTGTGTTT 
CXCL5 R ACTTCCACCTTGGAGCACTG 
CXCL9 (MIG) F GGTGGTGTTCCTCTTTTGTTGAGT 
CXCL9 (MIG) R GGAACAGCGTCTATTCCTCATTG 
CXCL10 (IP10) F CTTTGAACCAAAGTGCTGTTCTTATC 
CXCL10 (IP10) R AGCGTGTAGTTCTAGAGAGAGGTACTC 
CXCL 11 F AGAGGACGCTGTCTTTGCAT 
CXCL 11 R TGGGATTTAGGCATCGTTGT 
CXCL12 F ACAGATGTCCTTGCCGATTC 
CXCL12 R CCACTTCAATTTCGGGTCAA 
CXCL 13 F TCCAAGGTGTTCTGGAGGTC 
CXCL 13 R GGGAATCTTTCTCTTAAACACTGG 
CXCL 14 F CCCTCCGGTCAGCATGAG 
CXCL 14 R CCAGGCGTTGTACCACTTG 
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3.3.2 Results 
Ferret cytokine and chemokine specific real-time PCR primers 
Primers specific toward ferret cytokine and chemokine genes were designed by ClustalW 
analysis. Primers for ferret interleukins (Table 2), ferret inflammatory cytokines (Table 3) 
and ferret CC and CXC chemokines (Table 4) are described. 
Induction of TNF-α target genes by treatment of ferret blood cells with recombinant 
ferret TNF-α  
Once confirming that the recombinant TNF-ǂ protein was of proper molecular weight, we 
then went on to assess the biological potential of the recombinant protein in vitro. Ferret 
whole peripheral blood was stimulated with recombinant ferret TNF-ǂ and the RNA was 
extracted. Following extraction, the expression level of a panel of known TNF-ǂ target 
cytokine/chemokine genes were measured by real-time PCR. CXCL8 (120-fold), IFN-Ǆ (12-
fold), IL-1R (6-fold), IL-6 (3-fold) and IL-1ǃ (2-fold) were increased following stimulation 
(Figure 8). These results indicated that the recombinant ferret TNF-ǂ protein had biological 
activity.  
 
Fig. 8. Real-Time PCR analysis of ferret cytokines transcript stimulated by TNF-ǂ 
3.4 Development of IFN-γ and TNF-α hybridoma clones  
The generation of monoclonal antibodies specific to ferret IFN-Ǆ and TNF-ǂ are vital to the 
development of ELISAs and ELISPOTs. In this section we outline the development of these 
monoclonal antibodies using recombinant IFN-Ǆ and TNF-ǂ conjugated to a carrier protein, 
KLH (keyhole limpet hemocyanin) using glutaraldehyde. Furthermore, the KLH-IFN-
Ǆ/TNF-ǂ complexes injected and cell fusion to establish IFN-Ǆ/TNF-ǂ reactive B cell 
hybridomas is described along with downstream hybridoma clones slection.  
3.4.1 Methods 
Monoclonal anti-ferret TNF-α antibody production  
Monoclonal antibodies to recombinant ferret TNF-ǂ were manufactured by Open 
Biosystems (Birmingham, AL, USA).  
Mouse B cell hybridoma preparation for anti-ferret-IFN-γ 
Recombinant ferret IFN-Ǆ (50 µg) along with 2 mg of keyhole limpet hemocyaine (KLH) 
(Calbiochem, San Diego, CA, USA) were diluted in 0.5 ml PBS. Five µl of glutaraldehyde 
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were added and the mixture was incubated for 1 hr at room temperature. The whole 
mixture was washed on a spin column (Nanosep 10k OMEGA, Pall Life Science) and then 
concentrated to 0.1 ml volume. PBS (0.5 ml) was then added and the mixture was 
centrifuged. After two PBS washes, the mixture was filled to 0.5 ml with PBS. This mixture 
was used as the priming antigen. Mice were immunized with 25 µl antigen suspension in 
emulsified Complete Freund's Adjuvant and further injected at bi-weekly intervals with 5 
µg of recombinant ferret IFN-Ǆ. Three days following the third injection, spleen cells were 
removed and isolated for fusion with Sp2/0-Ag14 using polyethylene glycol (Roche, 
Mannheim, Germany). HAT (hypoxanthine aminopterin thymidine) resistant hybridomas 
were selected. Hybridoma cells were screened for the reactivity against IFN-Ǆ by ELISA 
using Nunc MaxiSorp 96 well plates coated with ferret IFN-Ǆ (100 µl, 0.1 µg/ml). 
3.4.2 Results 
Monoclonal ferret TNF-α antibody recognizes endogenous TNF-α isolated secreted from 
mitogen-stimulated ferret blood cells  
A monoclonal anti-ferret TNF-ǂ antibody was commercially manufactured by immunizing 
mice with recombinant ferret TNF-ǂ. Isolated ferret peripheral blood cells were then 
stimulated with the mitogens: SEB (Staphylococcal enterotoxin B), IFN-Ǆ, ionomycin and 
PMA plus ionomycin. Following stimuation, cell supernantants were run on SDS-PAGE and 
analyzed by western blotting using the manufactured monoclonal ferret TNF-ǂ antibody. 
Endogenous ferret TNF-ǂ protein was recognized in samples that had been stimulated with 
SEB, IFN-Ǆ and PMA plus ionomycin. In contrast, TNF-ǂ was not present in the supernatant 
from cells treated with ionomycin alone or unstimulated cells (Figure 9). These results 
suggested that the manufactured ferret monoclonal TNF-ǂ antibody was able to recognize 
endogenous secreted ferret TNF-ǂ. 
 
 
PBMCs were isolated and stimulated with SEB (100 μg/ml), IFN-Ǆ (2000IU/ml), ionomycin alone (1 
ug/ml) or PMA (50 ng/ml) with ionomycin (1 μg/ml), for 24 hrs at 37ºC. Cell supernatant was run on 
SDS-PAGE and subjected to western blotting with a monoclonal antibody (2μg/ml) against 
recombinant ferret TNF-ǂ. 
Fig. 9. Ferret monoclonal TNF-ǂ  antibody recognizes secreted endogenous TNF-ǂ.  
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Generation of monoclonal Abs specific for ferret IFN-γ 
Prior to the generation of ferret IFN-Ǆ monoclonal antibodies, we attempted to monitor IFN-
Ǆ levels from ferret cell cultures using human and mouse commercially available cytometric 
bead arrays. Neither human nor mouse-specific arrays resulted in the positive detection of 
ferret IFN-Ǆ. The failure in detection was most likely due to the inablility of the human and 
mouse IFN-Ǆ antibody to recognize the ferret IFN-Ǆ protein. These results prompted us to 
generate our own monoclonal antibodies specific to ferret IFN-Ǆ. To produce ferret IFN-Ǆ 
specific antibodies, recombinant IFN-Ǆ was conjugated to a carrier protein, KLH (keyhole 
limpet hemocyanin) using glutaraldehyde (as described in the methods). The resulting 
KLH-IFN-Ǆ complex was injected intraperitoneal into Balb/c mice. Following fusion of 
splenocytes with hybridoma parent cells, IFN-Ǆ-reactive B cell hybridomas were established 
and clones were selected by ELISA reactivity. Clone 1H1H12 and 4A4B7 recognized 
recombinant ferret IFN-Ǆ evident by a 40 kDa band (Figure 10).  
 
Fig. 10. Ferret IFN-Ǆ monoclonal antibody detects recombinant and endogenous ferret IFN-Ǆ 
protein.  
Lysates from COS-7 cells transfected with recombinant ferret IFN-Ǆ samples were analyzed 
by western blot using a monoclonal antibody established from mouse immunized by 
recombinant ferret IFN-Ǆ (left panel). Supernatants derived from ferret PBMC cultures 
stimulated with PMA plus ionomycin, were also analyzed by western blot using anti-ferret 
IFN-Ǆ monoclonal antibody (right panel). Arrows at the right of each panel indicate the 
dimers for lower molecular weight protein bands and putative tetramer as higher molecular 
weight species. 
3.5 ELISA and ELISPOT assays for the ferret cytokine IFN-γ 
An important application for monoclonal anti-ferret IFN-Ǆ antibodies is the detection and 
quantitation of IFN-Ǆ protein in biological samples. In this section the protocols for both 
IFN-Ǆ ELISA and ELISPOT are described. This includes the selection and testing of the 
monoclonal antibodies and ELISAs to measure IFN-Ǆ levels in sera obtained from influenza 
A-infected ferrets. Furthermore, a ferret-specific IFN-Ǆ ELISPOT assay is outlined using the 
same set of monoclonal ferret IFN-Ǆ antibodies used in the ELISA.  
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3.5.1 Methods 
Ferret IFN-γ-specific ELISA 
ELISA plates (96-well) (MaxiSorb, Nunc) were coated with 100 µl/well with monoclonal 
anti-IFN-Ǆ (2 µg/ml) overnight at 4oC. Wells were blocked with 150 µl 1% BSA in PBS for 1 
hour at 37oC. Supernatants from mitogen-stimulated PBMC cultures or serum from 
influenza A virus infected ferrets were loaded into the wells at appropriate dilutions and 
incubated for 1 hour at 37oC. Wells were washed with PBS/0.5% Tween-20 and then 
incubated for 1 hour at room temperature with biotin conjugated anti-IFN-Ǆ antibody (1 
µg/ml in 0.5% Tween-20/1%BSA). Following secondary antibody incubation, the wells 
were washed three times with PBS/0.5% Tween-20 before incubation with HRP-Avidin for 
30 minutes. The substrate, (o-phenylenediamine, Sigma) was applied for 15 minutes at room 
temperature. Colorimetric changes were quantitated using an automated ELISA reader 
(µQuant, BIO-TEK Instruments, Winooski, VT, USA). 
 
ELISA plate wells were coated with a monoclonal anti-ferret antibody.  Recombinant ferret IFN-Ǆ was 
sequentially diluted and added to the wells. Ferret IFN-Ǆ was detected by a second monoclonal anti-
ferret IFN-Ǆ biotin conjugated antibody. Logarithmic dilution was used to derive a standard curve for 
downstream applications of the ELISA.  
Fig. 11. Recombinant IFN-Ǆ protein quantification by ELISA.  
Ferret IFN-γ-specific ELISPOT assay 
PVDF plates (Millipore, MAIPS4510) or MaxiSorp plates (Nunc) were coated with a 
monoclonal anti-ferret IFN-Ǆ antibody, and subsequently blocked with 1% BSA in PBS. 
Isolated ferret PBMCs from peripheral blood were stimulated for 18 hours. The wells were 
then washed with water to remove cells and captured IFN-Ǆ was detected by a biotin-
conjugated detection antibody coupled to HRP-avidin (Sigma). The ELISPOT was 
developed using DAB (Vector Laboratories, Burlingame, CA, USA). 
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3.5.2 Results  
Detection of ferret IFN-γ by ELISA and ELISPOT immunoassays 
An important application for monoclonal antibodies is the detection and quantitation of 
protein in biological samples. Here we tested our monoclonal antibodies for use in a ferret 
IFN-Ǆ-specific ELISA by first determining the antibody pair for IFN-Ǆ recognition. Clone 
4A4B7 was conjugated to biotin and used as the detection antibody against ferret IFN-Ǆ. 
Clone 1H1H12 was used to coat the assay wells and be used as a capture antibody.  
This clone pair showed an increased optical density that correlated directly with the 
concentration of purified recombinant IFN-Ǆ (Figure 11).  
 
IFN-Ǆ ELISA was performed on supernantant from isolated ferret PMBCs treated with ConA. Results 
represent the mean values of triplicate samples. 
Fig. 12. ELISA detection of IFN-Ǆ from mitogen-stimulated PBMCs. 
We then used the ELISA assay to detect endogenous IFN-Ǆ from ConA-stimulated ferret 
PBMCs. Our assay showed that IFN-Ǆ was only present in samples that were treated with 
ConA and no detection in the negative control unstimulated samples (Figure 12). These 
results indicated that the monoclonal antibodies selected are applicable for ferret IFN-Ǆ-
specific ELISA and that the pair was a reliable detection system.  
ELISPOT assays are also key tools in the determining the activation of cellular immune 
responses. Specifically, ELISPOT assays directly quantitate the number of cytokine secreting 
cells as opposed to the ELISA which quantitates the amount of cytokine produced. To 
develop a ferret-specific IFN-Ǆ ELISPOT assay we employed the same set of monoclonal 
ferret IFN-Ǆ antibodies, clone 4A4B7 and 1H1H12. Isolated ferret PBMCs were subjected to 
an ELISPOT assay (as described in the methods) with stimulation of ConA. As expected, 
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increasing numbers of IFN-Ǆ secreting cells were detected in direct proportion to the 
number of stimulated cells plated. Furthermore, the number of IFN-Ǆ positive cells did not 
increase above background when increasing numbers of unstimulated cells were plated 
(Figure 13). These results suggested that 4A4B7 and 1H1H12 anti-ferret IFN-Ǆ monoclonal 
antibodies will be useful for not only quantitating ferret IFN-Ǆ levels but also for 
quantitating IFN-Ǆ producing ferret cells in an ELISPOT assay.  
 
ELISPOT assay was performed in the same manner outlined for Figure 12 for capture and detection. 
PBMCs were plated and stimulated with ConA 18 hours and IFN-Ǆ secreting cells were captured and 
detected by biotinylated IFN-g antibody.  
Fig. 13. ELISPOT assay for the IFN-Ǆ producing cells in mitogen-stimulated ferret PBMCs.  
4. Conclusion 
The development of ferret specific immune reagents will significantly improve knowledge 
gained by ferret infectious disease studies. The importance of the ferret as an animal model 
in the study of respiratory diseases is increasing. Currently, the use of the ferret model to 
investigate the immune response as well as immunotherapeutics in respiratory infections by 
viruses such as SARS CoV and influenza has been slowed by the lack of immunological 
reagents and immune response assessment tools. In this chapter we highlighted immune 
reagents and immunoassays that are successful at monitoring the ferret immune response, 
specifically focusing on cytokines.  
Currently, there is much interest to determine the immunological role of TNF-ǂ during 
influenza infection, as TNF-ǂ is thought to play a pathogenic role in other respiratory 
infections (Headley, Tolley, & Meduri, 1997). Here we have described the cloning and 
sequence of the ferret TNF-ǂ gene with the purpose of generating reagents and assays for 
the investigation of ferret immune responses. With the generated ferret TNF-ǂ expression 
vector we were able to express and purify recombinant protein for downstream uses. 
Importantly, the recombinant ferret TNF-ǂ protein was able to stimulate ferret peripheral 
blood cells and induce the expression of TNF-ǂ target genes such as: CXCL-8, IFN-Ǆ, IL-1ǃ, 
IL-6 and IL-1R (Vassalli, 1992; Baumann & Gauldie, 1994; Dinarello, 1996; Gabay & Kushner, 
1999). Furthermore, we have successfully generated monoclonal antibodies that specifically 
recognized ferret TNF-ǂ as well as primers that measured TNF-ǂ transcripts in cells 
stimulated with LPS, a known stimulant of TNF-ǂ (Curnis & Corti, 2004; Mestan et al., 1986; 
Wang et al., 1985). In summary, we have cloned, sequenced and expressed recombinant 
ferret TNF-ǂ and demonstrated its biological activity. Our ferret TNF-ǂ protein has enabled 
us to generate several useful reagents that will be important tools for immune modeling in 
respiratory diseases. 
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IFN-Ǆ is an essential regulator in the viral host immune response. Here the cloning  
of a full length ferret IFN-Ǆ and expression of the recombinant IFN-Ǆ protein was 
described. Furthermore, we described the generation of two monoclonal antibodies 
specific for ferret IFN-Ǆ and the subsequent development of immunoassays for the 
detection of native IFN-Ǆ. We anticipate that the IFN-Ǆ immunoassays established in this 
study will be useful in gaining insight into ferret antiviral responses and in other immune 
processes in general.  
Previous studies on IFN-Ǆ have shown that there is a strict species-specific activity of IFN-Ǆ. 
IFN-Ǆ genes isolated from diverse species such as guinea pig, turkey, rhino, and catfish have 
been previously described in the literature (Jeevan et al., 2006; Loa, Hsieh, Wu, & Lin, 2001; 
Milev-Milovanovic et al., 2006; Morar et al., 2007; Svitek & von, V, 2007). Our monoclonal 
antibodies detected recombinant IFN-Ǆ in Western blotting. These two clones were paired 
successfully during the development of ferret IFN-Ǆ-specific ELISA and ELISPOT bioassays. 
Previously, we infected ferrets with H3N2 influenza A strain (A/Panama/2007/99) and 
sampled serum from the animals 6 days post infection (Ochi et al., 2008). The ELISA showed 
a marked increase in the levels of circulating IFN-Ǆ on day 6 post-infection compared to the 
uninfected control. Specifically, the level of IFN-Ǆ in serum from the non-infected control 
ferret was below the detection limit. These results suggested that our developed ELISA 
assay for quantitation of ferret IFN-Ǆ will be invaluable in monitoring systemic IFN-Ǆ 
responses during a host response against virus infection.  
There is an overwhelming need for experimental models that enable the evaluation of 
therapeutic treatments and vaccines for use in infectious diseases such as emerging 
influenza viruses. Ferrets have been used as an animal model of infection with influenza A 
viruses to test the severity of the disease and also to evaluate efficacy of potential vaccines 
(Suguitan, Jr. et al., 2006; Cameron et al., 2008; Danesh et al., 2011; Rowe et al., 2010b). 
Specifically, TNF-ǂ and IFN-Ǆ have been identified as major inducers of pathogenesis in 
respiratory illnesses which includes SARS (Cheung et al., 2005), (Roberts & Subbarao, 2006) 
and influenza virus (Maher & DeStefano, 2004; Cheung et al., 2002; de Jong et al., 2006). 
From these findings comes the hypothesis that these inflammatory cytokines may be the key 
to potential future therapies.  
TNF-ǂ antibodies have been shown to have therapeutic potential in disease either as 
therapeutic targets or as biomarkers. In a mouse model of influenza-induced pneumonia, a 
neutralizing antibody to TNF-ǂ significantly reduced the lung pathology and prolonged 
survival of infected animals thereby suggesting TNF-ǂ as a therapeutic target (Peper & Van, 
1995). With the antibodies generated, it is now possible to investigate the therapeutic 
potential of targeting TNF-ǂ to modulate the immunopathology during influenza infection. 
Alternatively, IFN-Ǆ has been shown to be a useful biomarker. ELISPOT and ELISA assays 
are excellent techniques that can be employed in studies monitoring vaccine and therapeutic 
efficacy by measuring the levels of biomarkers such as IFN-Ǆ. Taken together, these reagents 
will be helpful in the assessment of vaccine efficacy against influenza A and other emerging 
infectious viruses. 
In conclusion, this work has expanded the potential of the ferret model for respiratory 
disease investigation as well as other diseases that involved the immune response.  
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